| Title |
Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies
|
|---|---|
| Published in |
Molecular Cancer Therapeutics, July 2018
|
| DOI | 10.1158/1535-7163.mct-17-1299 |
| Pubmed ID | |
| Authors |
Peter Makhov, Shreyas Joshi, Pooja Ghatalia, Alexander Kutikov, Robert G Uzzo, Vladimir M Kolenko |
| Abstract |
Renal cell carcinoma (RCC) is the most common form of kidney cancer. It is categorized into various subtypes, with clear cell RCC (ccRCC) representing about 85% of all RCC tumors. The lack of sensitivity to chemotherapy and radiation therapy prompted research efforts into novel treatment options. The development of targeted therapeutics, including multi-targeted tyrosine kinase inhibitors (TKI) and mTOR inhibitors, has been a major breakthrough in ccRCC therapy. More recently, other therapeutic strategies, including immune checkpoint inhibitors, have emerged as effective treatment options against advanced ccRCC. Furthermore, recent advances in disease biology, tumor microenvironment, and mechanisms of resistance formed the basis for attempts to combine targeted therapies with newer generation immunotherapies to take advantage of possible synergy. This review focuses on the current status of basic, translational, and clinical studies on mechanisms of resistance to systemic therapies in ccRCC. Mol Cancer Ther; 17(7); 1355-64. ©2018 AACR. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 185 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 185 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 31 | 17% |
| Student > Master | 22 | 12% |
| Researcher | 17 | 9% |
| Student > Bachelor | 17 | 9% |
| Student > Doctoral Student | 10 | 5% |
| Other | 22 | 12% |
| Unknown | 66 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 38 | 21% |
| Medicine and Dentistry | 33 | 18% |
| Agricultural and Biological Sciences | 10 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 5% |
| Immunology and Microbiology | 5 | 3% |
| Other | 19 | 10% |
| Unknown | 70 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 September 2022.
All research outputs
#1,621,234
of 23,341,064 outputs
Outputs from Molecular Cancer Therapeutics
#156
of 3,905 outputs
Outputs of similar age
#36,046
of 328,832 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#6
of 48 outputs
Altmetric has tracked 23,341,064 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,905 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,832 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.